Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PRCY - ANY BODY HAS ANY NEWS ON THESE -- Ignore unavailable to you. Want to Upgrade?

To: D.Lu who wrote (294)	12/16/1997 4:02:00 PM
From: Coha	Read Replies (1) \| Respond to of 670

I don't expect a change in focus. Clearly, however, there will be more time now to focus on the other parts of the strategy, namely selling the niche products. That is the absolute number 1 priority now, bar none. Get $$ onto the books now and begin a cash flow. I imagine they will continue to consider contract manufacturing a priority as well for the added revenue. However I do not expect new products out of the pipeline. In fact I hope and expect that they will continue to whiddle r&d down as well as other expenses and save their cash. This company does not have the luxury of developing new products, at least not in the short term; they need to scrimp and save every dollar as they build sales. Once that is accomplished, then absolutely, go for the r&d. But survival is the issue at hand. I am interested in seeing how this agreement with Bard reflects on their top line in the next year. In the meantime, their clear focus now, IMO, is developing the market for their niche products. Coha